MedTrace Logo

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00331916 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2009-09-29

No results posted yet for this study

Summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

quinolone

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Stella Robertson, Ph.D. · Study Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331916 on ClinicalTrials.gov